Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for collagen crosslinks testing, effective May 15, 2026. Here's what billing teams need to know before that date.
CMS collagen crosslinks coverage policy has been updated under a policy modification that takes effect May 15, 2026. The Centers for Medicare & Medicaid Services governs this testing category, which covers biochemical markers used to assess bone resorption—most commonly ordered in osteoporosis management. This policy does not list specific CPT or HCPCS codes in the available data, but collagen crosslinks billing is directly affected and your team needs to act before the effective date.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Collagen Crosslinks, any Method |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium |
| Specialties Affected | Endocrinology, rheumatology, orthopedics, primary care, clinical laboratory |
| Key Action | Review your collagen crosslinks billing workflows and medical necessity documentation before May 15, 2026 |
CMS Collagen Crosslinks Coverage Criteria and Medical Necessity Requirements 2026
Collagen crosslinks testing measures bone resorption markers. The most common markers in this category are urinary and serum N-telopeptide, C-telopeptide (CTX), and pyridinoline crosslinks. These tests get ordered most often to monitor response to osteoporosis treatment—specifically, to confirm that antiresorptive therapy is working.
The CMS coverage policy for collagen crosslinks has historically been restrictive. Medicare's position has long been that these tests are covered only when specific medical necessity criteria are met. The core question CMS asks: is this test changing clinical management? If the answer isn't clearly documented in the chart, you're looking at a claim denial.
Medical necessity documentation is everything here. CMS requires that the ordering physician document why the result will change treatment. "Monitoring osteoporosis" by itself is not enough. Your documentation needs to show a clinical decision point—starting therapy, switching agents, or confirming biochemical response after a defined treatment period.
Prior authorization is not typically required for lab testing under Medicare Part B. But the absence of a prior authorization requirement doesn't reduce your exposure. CMS audits these claims on the back end, and insufficient medical necessity documentation is the most common reason for denial and post-payment recoupment.
The modification effective May 15, 2026 signals that CMS has reviewed this coverage policy and made changes. Because the full policy detail is not available in the current data, your billing team should pull the source policy directly at the CMS or relevant Medicare Administrative Contractor level before the effective date. If your practice bills these tests regularly, loop in your compliance officer now—don't wait until May.
CMS Collagen Crosslinks Exclusions and Non-Covered Indications
CMS has consistently treated certain uses of collagen crosslinks testing as non-covered. These exclusions show up repeatedly in Local Coverage Determinations issued by Medicare Administrative Contractors across the country.
Routine screening in patients without a confirmed osteoporosis diagnosis or fracture risk assessment is not covered. CMS does not consider these tests medically necessary for general population screening, regardless of age or risk factors.
Testing in patients already on stable long-term antiresorptive therapy—where no clinical decision is pending—is another common denial trigger. If the test result won't change what you're doing, CMS takes the position that the test is not medically necessary.
Repeated testing within short intervals is also a red flag. Most LCD guidance sets a minimum interval between tests, often six months or longer. Billing multiple tests within that window without documentation of a specific clinical reason will draw scrutiny and likely generate a claim denial.
Collagen crosslinks testing ordered as a reflex panel—bundled with bone density or other labs without a specific indication—has also faced non-coverage determinations. Each test needs its own documented indication.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Monitoring response to antiresorptive therapy in confirmed osteoporosis | Covered (when medical necessity criteria met) | Not listed in policy data | Requires documentation of clinical decision point; interval limits apply |
| Routine screening without confirmed osteoporosis diagnosis | Not Covered | Not listed in policy data | Not considered medically necessary by CMS |
| Testing during stable long-term therapy with no pending clinical decision | Not Covered | Not listed in policy data | Fails medical necessity standard |
| Repeated testing within minimum interval without specific clinical justification | Not Covered | Not listed in policy data | Interval requirements apply; check applicable LCD |
| Reflex panel testing without specific documented indication | Not Covered | Not listed in policy data | Each test requires individual medical necessity documentation |
Note: This policy does not list specific CPT or HCPCS codes in the available data. See the Affected Codes section below for guidance.
CMS Collagen Crosslinks Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull the full policy text before May 15, 2026. The available data for this modification does not include the complete policy detail. Go to the CMS source directly or check your Medicare Administrative Contractor's LCD database. Your MAC may have a corresponding LCD that provides more granular coverage criteria than the national policy. |
| 2 | Audit your medical necessity documentation now. For every collagen crosslinks claim your practice submits, the chart must document why the result changes clinical management. "Rule out osteoporosis" or "bone health monitoring" is not sufficient. Your billing team should review the ordering documentation against CMS's medical necessity standard before claims go out the door. |
| 3 | Check your testing intervals. Most MAC-level LCDs tied to this coverage policy set minimum intervals between tests. Pull your claim history for the past 12 months and flag any cases where tests were billed more frequently than the applicable interval allows. Fix your charge capture workflow to build in an interval check. |
| 4 | Update your ABN process for marginal cases. If a patient requests collagen crosslinks testing but the clinical indication is borderline—or the interval hasn't been met—issue an Advance Beneficiary Notice of Noncoverage before the test is performed. This protects your practice and gives the patient the option to self-pay. Don't bill Medicare for tests you know won't meet medical necessity. |
| 5 | Review your ICD-10 coding for linked diagnoses. Reimbursement depends on linking the test to an appropriate diagnosis code that supports medical necessity. Osteoporosis diagnosis codes, fracture history codes, and codes documenting current antiresorptive therapy are the typical supporting diagnoses. Make sure your coders aren't defaulting to unspecified codes when more specific options are available. |
| 6 | Talk to your compliance officer if you have high volume. Practices that bill collagen crosslinks tests in significant numbers—endocrinology, rheumatology, and clinical labs especially—face more audit exposure than low-volume billers. If your team isn't certain how this modification applies to your patient mix, get your compliance officer involved before May 15, 2026. This is not the policy change to interpret conservatively on your own. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Collagen Crosslinks Under This Policy
The policy data for this modification does not include specific CPT, HCPCS, or ICD-10 codes. This is a known limitation of the available data—not an indication that no codes apply.
What Your Team Should Do
Collagen crosslinks testing is typically billed under a small set of lab CPT codes for specific crosslink markers. Your Medicare Administrative Contractor's LCD for this testing category will list the covered and non-covered codes applicable in your region. LCDs vary by MAC, so the codes that trigger coverage—and the codes that don't—may differ depending on where your practice is located.
Do not assume the code list from a prior version of this policy still applies after May 15, 2026. The modification may have added, removed, or reclassified specific codes. Pull the current code list from your MAC's LCD portal directly.
Finding the Right Codes
Search your MAC's LCD database for "collagen crosslinks" or "bone resorption markers." The LCD will include a Billing and Coding Article that lists covered CPT codes, non-covered CPT codes, and the ICD-10-CM diagnosis codes that support medical necessity. That article is the controlling document for your billing team—not this blog post and not a prior-year fee schedule.
If you can't locate the applicable LCD or if your MAC hasn't issued one, the national CMS policy governs. Contact your MAC's provider relations line if you need clarification on which document applies to your claims.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.